

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : G01N 33/53, C12Q 1/70, 3/00	A1	(11) International Publication Number: <b>WO 00/25134</b>  (43) International Publication Date: 4 May 2000 (04.05.00)																					
<p>(21) International Application Number: PCT/US99/24956</p> <p>(22) International Filing Date: 22 October 1999 (22.10.99)</p> <p>(30) Priority Data:</p> <table border="0"><tr><td>60/105,390</td><td>23 October 1998 (23.10.98)</td><td>US</td></tr><tr><td>60/135,097</td><td>23 December 1998 (23.12.98)</td><td>US</td></tr><tr><td>60/134,836</td><td>19 May 1999 (19.05.99)</td><td>US</td></tr></table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table border="0"><tr><td>US</td><td>60/105,390 (CIP)</td></tr><tr><td>Filed on</td><td>23 October 1998 (23.10.98)</td></tr><tr><td>US</td><td>60/135,097 (CIP)</td></tr><tr><td>Filed on</td><td>23 December 1998 (23.12.98)</td></tr><tr><td>US</td><td>60/134,836 (CIP)</td></tr><tr><td>Filed on</td><td>19 May 1999 (19.05.99)</td></tr></table> <p>(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BLANCHARD, Steven, Gerard [US/US]; Glaxo Wellcome Inc., Five Moore Drive,</p>		60/105,390	23 October 1998 (23.10.98)	US	60/135,097	23 December 1998 (23.12.98)	US	60/134,836	19 May 1999 (19.05.99)	US	US	60/105,390 (CIP)	Filed on	23 October 1998 (23.10.98)	US	60/135,097 (CIP)	Filed on	23 December 1998 (23.12.98)	US	60/134,836 (CIP)	Filed on	19 May 1999 (19.05.99)	<p>P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US). PARK, Derek, J. [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US). STIMMEL, Julie, Beth [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US).</p> <p>(74) Agents: LEVY, David, J.; Glaxo Wellcome Inc., Intellectual Property Dept., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US) et al.</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b></p> <p><i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
60/105,390	23 October 1998 (23.10.98)	US																					
60/135,097	23 December 1998 (23.12.98)	US																					
60/134,836	19 May 1999 (19.05.99)	US																					
US	60/105,390 (CIP)																						
Filed on	23 October 1998 (23.10.98)																						
US	60/135,097 (CIP)																						
Filed on	23 December 1998 (23.12.98)																						
US	60/134,836 (CIP)																						
Filed on	19 May 1999 (19.05.99)																						
(54) Title: ASSAYS FOR LIGANDS FOR NUCLEAR RECEPTORS																							
<p>(57) Abstract</p> <p>The present invention includes new nuclear receptor heterodimer and nuclear receptor-coactivator peptide assays for identifying ligands for nuclear receptors, utilizing <u>scintillation proximity and fluorescence resonance energy transfer (FRET)</u>.</p>																							

## ASSAYS FOR LIGANDS FOR NUCLEAR RECEPTORS

5

### Cross reference to Related Applications

This application claims benefit under 35 U.S.C.119(e) of US provisional applications 60/150,390 filed 23 October 1998; 60/135,097 filed 23 December 1998; and 60/134,836 filed 19 May 1999.

10

### Background of the Invention

Identification of ligands for orphan nuclear receptors has traditionally made use of either cell-based reporter gene assays or, in those cases where some ligand is known, competition binding assays. Both the transactivation and ligand-binding assays typically used to determine activity of putative nuclear receptor activators assess the effect of test ligands on an isolated receptor. The available evidence, however, indicates that a large proportion of the known orphan nuclear receptors, including the LXRs and FXR (1,2,8), function as heterodimeric receptor complexes with the common dimerization partner, RXR (reviewed in 6). Recently, it has been demonstrated that certain synthetic RXR ligands exhibit preferential activation of RXR heterodimers, and that this preference is determined by the receptor partner bound to RXR (7). These findings suggested the possibility that ligand binding to, and therefore subsequent activation of, nuclear receptors may be modulated by the receptor's dimerization state. Further, microscopic reversibility implies that ligand binding should modulate heterodimer affinity. Therefore, the ability of a ligand to induce changes in the degree of receptor dimerization could be used as the basis for a novel assay for the discovery of nuclear receptor ligands.

FXR is an orphan nuclear receptor initially identified from a rat liver cDNA library (8) that is most closely related to the insect ecdysone receptor. The ligand binding domain of the receptor was cloned and expressed in support of an effort to develop a robust assay to identify a novel ligand. The

availability of ligands for FXR will aid in the elucidation of the physiological role of this receptor. In addition, the information gained will further increase understanding of nuclear receptors as a target class.

For both FXR and LXR, a basal level of nuclear receptor-RXR $\alpha$  heterodimer formation is observed in the absence of added ligand. Ligands that promote heterodimer formation induce a concentration-dependent increase in time-resolved fluorescent signal. Compounds which bind equally well to both monomeric receptor and to the receptor: RXR $\alpha$  heterodimer would be expected to give no change in signal, whereas ligands which bind preferentially to the monomeric receptor would be expected to induce a concentration-dependent decrease in the observed signal.

### Summary of the Invention

The present invention includes a generic approach to assay development for nuclear receptors, utilizing purified ligand binding domains. The concept of generic assay development has been extended to develop in vitro assays that detect ligand binding by monitoring ligand induced changes in receptor heterodimerization. This approach has been demonstrated using both scintillation proximity and homogenous time-resolved fluorimetry (HTRF) in the accompanying examples but it is not restricted to these methods. Other marking and measuring techniques may also be used. However, the use of scintillation proximity or HTRF provides a simpler and more practical methodology.

Another aspect of the invention is a new nuclear receptor-peptide assay for identifying ligands. This assay utilizes fluorescence resonance energy transfer (FRET) and was used to test whether putative ligands bound to FXR.

The FRET assay is based upon the principle that ligands induce conformational changes in nuclear receptors that facilitate interactions with coactivator proteins required for transcriptional activation.

In FRET, a fluorescent donor molecule transfers energy via a non-radiative dipole-dipole interaction to an acceptor molecule (which is usually a fluorescent

molecule). FRET is a standard spectroscopic technique for measuring distances in the 10-70Å range. Upon energy transfer, which depends on the  $R^{-6}$  distance between the donor and acceptor, the donor's fluorescence is reduced, and the acceptor fluorescence is increased, or sensitized. FRET is frequently used in  
5 both polymer science and structural biology and has recently been used to study macromolecular complexes of DNA, RNA, and proteins. In addition, Mathis has used europium cryptates with the multichromophoric Allophycocanin to achieve an extremely large  $R_0$  of 90Å Mathis, G. (1993) Clin. Chem. 39, 1953-1959.

10

### Brief Description of the Drawings

**Fig. 1.** As shown in Fig 1, ligand binding to LXRβ measured by modulation of LXRβ:RXR heterodimer formation.

15

**Fig.2.** Fig. 2 shows ligand binding to FXR measured by modulation of FXR:RXR heterodimer formation.

### Detailed Description of the Invention

In the assay of the present invention a method is provided for the rapid  
20 and simple determination of a ligand for a nuclear receptor which comprises contacting a component to be tested with an isolated nuclear receptor ligand binding domain which may be associated with a marking component, and a dimerization partner for the nuclear receptor ligand binding domain which is also associated with a marker; and measuring the interaction between the  
25 marking components to determine whether the component to be tested modifies heterodimerization. Various known markers may be used in the process of the present invention such as radioactive markers. The marker could also be a fluorescent dye. When the marker is radioactive, scintillation proximity may be used to measure the marker. When the marker used is a  
30 fluorescent dye, homogenous time-resolved fluorimetry may be used to detect the marker. Other known marking and measuring techniques may be used

depending on the marker. However, the markers need to be in close proximity to indicate heterodimerization. That is, to indicate that the component to be tested functions as a ligand for the dimerization pair.

RXRs, such as RXR $\alpha$ , RXR $\beta$ , and RXR $\gamma$ , PPARs, such as PPAR $\alpha$ , PPAR $\gamma$ , and PPAR $\delta$ , LXR  $\alpha$ ,  $\beta$ , ER $\alpha$ , ER $\beta$ , CAR  $\alpha$ , HNF4  $\alpha, \beta, \gamma$ , NGFIB  $\alpha, \beta, \gamma$ , PXR, PHR, EAR-1, EAR-2, TR, RAR, and ERRs are examples of nuclear receptors that may be used as the dimerization partners and/or the nuclear receptors in the process of the present invention. RXR $\alpha$  is exemplified in some of the examples. Any nuclear receptor can be selected for use in an assay. More dimerization partners may be known or later discovered which can readily be utilized in the assay. It is preferable that the dimerization partners and the nuclear receptor ligand binding domains are recombinant proteins and preferably are bacterial expressed.

This method for the rapid determination of a ligand for a nuclear receptor comprises contacting a component to be tested with an isolated nuclear receptor ligand binding domain which is associated with a first marking component, and a heterodimeric partner for the nuclear receptor ligand binding domain associated with a second marking component, and measuring the interaction between the marking components to determine whether the component to be tested modifies hetero-dimerization.

The first marking component may be a radioactive marker and the second marking component (or second marker) may be a SPA bead. The interaction of the markers in this case is determined by scintillation proximity. Alternatively, the first marking component may be a first fluorescent dye emitting at an emitting wavelength which excites the second marking component which may be a second fluorescent dye. The interaction of the markers in this case is determined by homogenous time-resolved fluorimetry.

The interaction of the marking components in either case is measured by comparing a signal produced by a combination of the heterodimeric partner, the isolated nuclear receptor binding domain and the component to be tested with a signal produced by a combination of the heterodimeric

partner and the isolated nuclear receptor ligand binding domain in the absence of the component to be tested.

#### Example 1

This example describes the use of ligand mediated heterodimerization  
5 to quantify ligand binding to the nuclear receptor, Liver X Receptor (LXR).

Liver X receptor alpha (LXR $\alpha$ ) is an orphan nuclear receptor initially identified from a rat liver cDNA library (1). Human LXR $\alpha$  (2) and LXR  $\beta$  (3) have also been identified. The ligand binding domains of these receptors were cloned and expressed in support of an effort to develop a robust assay  
10 to identify a novel ligand. Oxysterols, including 24(S),25- epoxycholesterol have been identified as weak activators for these receptors (4,5). The availability of more potent and selective ligands for the LXRs may aid in the elucidation of the physiological role(s) of these receptors. In addition, the information gained will further increase understanding of nuclear receptors as  
15 a target class.

This example describes the use of ligand mediated heterodimerization to quantify ligand binding to the nuclear receptor Liver X Receptor beta (LXR $\beta$ ). The method measures the ability of putative ligands to mediate the heterodimerization between the purified bacterial expressed LXR $\beta$ , and  
20 RXR $\alpha$ , ligand binding domains (LBD). Detection of the associated LBD's are measured by time resolved fluorimetry (TRF). The purified LBD of LXR $\beta$  is labeled with biotin then mixed with stoichiometric amounts of europium labeled streptavidin (Wallac Inc). The purified LBD of RXR $\alpha$  is labeled with CY5<sup>™</sup>. Equimolar amounts of each modified LBD are mixed together and  
25 allowed to equilibrate for at least one hour prior to the addition to either variable or constant concentrations of the sample for which the affinity is to be determined. After equilibration, the time-resolved fluorescent signal is quantitated using a fluorescent plate reader. The affinity of the test compound is estimated from a plot of fluorescence versus concentration of test  
30 compound added.

A basal level of LXR $\beta$ :RXR $\alpha$  heterodimer formation is observed in the absence of added ligand. Ligands that promote heterodimer formation induce a concentration-dependent increase in time-resolved fluorescent signal. Compounds which bind equally well to both monomeric LXR $\beta$  and to the  
5 LXR $\beta$ :RXR $\alpha$  heterodimer would be expected to give no change in signal, whereas ligands which bind preferentially to the monomeric receptor would be expected to induce a concentration-dependent decrease in the observed signal.

#### METHODS & MATERIALS

##### 10 Advance Preparation:

Human LXR $\beta$  Ligand Binding Domain (LXR  $\beta$  LBD; Genbank accession number U 07132, amino acids 185-461) was expressed in E.coli strain BL21 (DE3) as an amino-terminal polyhistidine tagged fusion protein. Expression was under the control of an IPTG inducible T7 promoter. DNA encoding this  
15 recombinant protein and a modified polyhistidine tag was subcloned into the expression vector pRSETa (Invitrogen).

Ten-liter fermentation batches were grown in Rich PO<sub>4</sub> media with 0.1 mg/mL Ampicillin at 25°C for 12 hours, cooled to 9°C and held at that temperature for 36 hours to a density of OD<sub>600</sub>=14. At this cell density, 0.25  
20 mL IPTG was added and induction proceeded for 24 hours at 9°C, to a final OD<sub>600</sub> =16. Cells were harvested by centrifugation (20 minutes, 3500g, 4°C), and concentrated cell slurries were stored in PBS at -8°C.

##### Purification of Receptor Ligand Binding Domain

25 Routinely, 30-40 g cell paste (equivalent to 2-3 liters of the fermentation batch) was resuspended in 300-400 mL TBS, pH 8.5 (25mM Tris, 150 mM NaCl). Cells were lysed by passing three times through a homogenizer (Rannie) and cell debris was removed by centrifugation (30 minutes, 20,000g, 4°C). The cleared supernatant was filtered through coarse pre-filters, and  
30 TBS, pH 8.5, containing 500 mM imidazole was added to obtain a final

imidazole concentration of 50mM. This lysate was loaded onto a column (6 x 8 cm) packed with Sepharose (Ni <sup>++</sup> charged) Chelation resin (Pharmacia) and pre-equilibrated with TBS pH 8.5/ 50mM imidazole. After washing to baseline absorbance with equilibration buffer, the column was developed with a linear  
5 gradient of 50 to 275 mM imidazole in TBS, pH 8.5. Column fractions were pooled and dialyzed against TBS, pH 8.5, containing 5% 1,2-propanediol, 5mM DTT and 0.5mM EDTA. The protein sample was concentrated using Centri-prep 10K (Amicon) and subjected to size exclusion, using a column (3 x 90 cm) packed with Sepharose S-75 resin (Pharmacia) pre-equilibrated with  
10 TBS, pH 8.5, containing 5% 1,2-propanediol, 5mM DTT and 0.5mM EDTA.

#### Biotinylation of LXR $\beta$

Purified LXR $\beta$ , LBD was desalted/buffer exchanged using PD-10 gel filtration columns into PBS [100mM Na Phosphate, pH 7.2, 150 mM NaCl]. LXR $\beta$  LBD was diluted to approximately 10 $\mu$ M in PBS and five-fold molar  
15 excess of NHS-LC-Biotin (Pierce) was added in a minimal volume of PBS. This solution was incubated with gentle mixing for 30 minutes at room temperature. The biotinylation modification reaction was stopped by the addition of 2000x molar excess of Tris-HCl, pH 8. The modified LXR  $\beta$  LBD was dialyzed against 4 buffer changes, each of at least 50 volumes, PBS  
20 containing 5mM DTT 2mM EDTA and 2% sucrose. The biotinylated LXR $\beta$  LBD was subjected to mass spectrometric analysis to reveal the extent of modification by the biotinylation reagent. In general, approximately 95% of the protein had at least a single site of biotinylation; and the overall extent of biotinylation followed a normal distribution of multiple sites, ranging from one  
25 to nine.

#### RXR $\alpha$ LBD

Human Retinoid X Receptor alpha Ligand Binding Domains:  
RXR-alpha LBD (amino acids 225-462) was expressed in E. coli strain BL21 (DE3) as an amino-terminal polyHistidine tagged fusion protein. Expression  
30 was under the control of an IPTG inducible T7 promoter. DNA encoding this



recombinant protein and a modified histidine tag was subcloned into the expression vector pRSETa (Invitrogen). The sequence used in the construction of RXR-alpha LBD was derived from Genbank accession number X52773.

- 5        Ten-liter fermentation batches were grown in Rich P<sub>0</sub><sub>4</sub> media with 0.1 mg/mL Ampicillin at 25°C for 12 hours, cooled to 9°C and held at that temperature for 36 hours to a density of OD<sub>600</sub> =14. At this cell density, 0.25 mM IPTG was added and induction proceeded for 24 hours at 9°C, to a final OD<sub>600</sub> =16. Cells were harvested by centrifugation (20 minutes, 3500g, 4°C),  
10      and concentrated cell slurries were stored in PBS at -8°C.

#### Protein purification

- Routinely, 40-50 g frozen cell paste (equivalent to 2-3 liters of the fermentation batch) was thawed and resuspended in 300mL TBS, pH 7.2,  
15      (25mM Tris, 150mM NaCl). Cells were lysed by three passages through a homogenizer (Rannie) and cell debris was removed by centrifugation (30 minutes, 20,000g, 4°C). The cleared supernatant was filtered through coarse pre-filters and TBS, pH 7.2, containing 500 mM Imidazole was added to obtain a final imidazole concentration of 50 mM. This lysate was loaded onto  
20      a column (3 x 8 cm) packed with Sepharose [Ni<sup>++</sup> charged] Chelation resin (Pharmacia) and pre-equilibrated with TBS, pH 7.2, containing 50mM imidazole. After washing to baseline absorbance, the column was developed with a linear gradient of 50 to 500 mM imidazole in TBS, pH 7.2. Column fractions were pooled and dialyzed against TBS, pH 7.2, containing 5 mM  
25      DTT and .5mM EDTA. After dialysis the sample was concentrated using Centri-prep 10K (Amicon) and subjected to size exclusion with a column (3 x 90 cm) packed with Sepharose S-75 resin (Pharmacia) pre-equilibrated with the same buffer.

- 30      Biotinylation of Human Retinoid-X Receptor Ligand Binding Domain

Purified RXR $\alpha$  LBD biotinylation was carried out in a manner similar to that described for LXR $\beta$  LBD.

Labeling of RXR $\alpha$  with CY5<sup>TM</sup>

Purified RXR $\alpha$  LBD was diluted to approximately 10 $\mu$ M in PBS and  
5 approximately five-fold molar excess of Cy5<sup>TM</sup> monofunctional reactive dye [NHS ester] (Amersham Life Sciences) was added in a minimal volume of PBS. This solution was incubated in the dark with mixing for 30 minutes at ambient room temperature (approximately 23°C). The modification reaction was stopped by the addition of an excess of Tris-HCl, pH 8. Fluorescent dye  
10 modified RXR $\alpha$  LBD was dialyzed at 4°C, with minimal exposure to light, against 4 buffer changes, each of at least 50 volumes, PBS containing 5mM DTT, 2mM EDTA, and 2% (w/v) sucrose. Aliquots were frozen on dry ice and stored at -80°C.

15 Preparation of CY5<sup>TM</sup> -RXR $\alpha$ :Streptavidin-(Europium Chelate)-LXR $\beta$  Complex

Equimolar concentrations of biotinylated LXR $\beta$ , and streptavidin-conjugated europium chelate were incubated in assay buffer containing 10 mM DTT for at least 10 minutes. To this solution equimolar concentrations of Cy5<sup>TM</sup> labeled RXR $\alpha$  was added and allowed to equilibrate for at least 30  
20 minutes. The premixed receptor was then added in a one-step addition to the compound plate, utilizing e.g., a Titertek Multidrop 384.

Materials:

Cy5<sup>TM</sup> RXR $\alpha$  and Europium labeled streptavidin LXR $\beta$  Complex

25

Assay Buffer: 50 mM KCl, 0.1 mg/mL BSA, 10 mM DTT and 50 mM Tris (pH 8) The stock buffer is made by dissolving 2.853g Tris base, 4.167 g Tris hydrochloride, 3.73 g KCl, and 0.1 g fatty acid free bovine serum albumin, in 1 L of deionized water. The pH is checked and adjusted to 8.0, if necessary,  
30 before adjusting to final volume. 0.154 g of solid DTT is added per 100 mL of

buffer just before the start of an experiment.

BSA, fatty acid free

DTT

5 KCl

Europium labeled Streptavidin: (Wallac CR28-100)

Tris Hydrochloride

96 well plates: polypropylene for intermediate dilutions (Costar #3794)

and either a clear-bottomed white SPA plates (Costar #3632) or a black

10 Polyftronics plate (UP350 PSB) for assays.

Methods:

Experimental Details:

Each well to be assayed contained a previously prepared solution of  
CY5™ RXRα and Europium labeled LXR and the desired concentration of  
15 test samples or controls (100μL total volume). In general, the total volume  
was held constant by varying the concentration and volume of premixed  
receptors to compensate for any changes in the volume of a particular set of  
samples. The plates were incubated for at least 2 hours at room temperature  
and the fluorescent signal determined in a Wallac Victor Multilabel

20 Fluorescence Reader.

Data Reduction:

For single concentration assays, the results of each test well were  
expressed as % of control, C, calculated according to eq. 1.

$$25 \quad C = 100 * \frac{F_{\text{sample}} - F_{\text{basal}}}{F_{\text{std}} - F_{\text{basal}}} \quad (1)$$

where  $F_{\text{sample}}$  is the signal observed in a particular sample well,  $F_{\text{total}}$  is the  
signal observed in the presence of control inhibitor and  $F_{\text{basal}}$  is the count rate  
30 observed in the presence of no ligand. The values used for  $F_{\text{std}}$  and  $F_{\text{basal}}$   
were averages of the corresponding control wells included on every plate.

For Dose response assays, the data were first normalized to % of control using eq. (1). A plot of  $C_L$ , the % of control observed at ligand concentration  $L$ , versus ligand concentration,  $L$  was constructed. The data were fit to equation (2) to obtain best-fit parameters for the  $EC_{50}$ ,  $F_{max}$  and

5  $F_{basal}$ .

$$C_L = F_{basal} + \frac{F_{max} * L}{EC_{50} + L} \quad (2)$$

- 10 Note that  $F_{max}$ , the maximal amplitude observed at saturating ligand concentrations, can be either a positive or negative value. The sign of this parameter indicates whether a particular test compound favors binding to the LXR:RXR complex (positive  $F_{max}$ ) or to either of the component receptors in a non-heterodimeric state (negative  $F_{max}$ ). Furthermore, both  $F_{max}$  and  $F_{basal}$  are
- 15 expressed in units of % of a standard compound.

## RESULTS

- Both the magnitude and sign of  $F_{max}$  (the maximal ligand-induced amplitude) must be considered. Note that the definition of the maximal
- 20 response observed for 24(S), 25-epoxycholesterol = 100% is an arbitrary assignment. The purpose of the normalization is only to allow comparison of values obtained for different compounds on different days and/or using different fluorescence plate readers. The results are shown in Figure 1.

### 25 Example 2

Determination of Ligand Binding to Farnasoid X Receptor: Retinoid X Receptor Heterodimer utilizing Time Resolved Fluorimetry.

- This example describes the use of ligand mediated heterodimerization to quantify ligand binding to the nuclear receptor Farnasoid X Receptor
- 30 (FXR).

The method measures the ability of putative ligands to mediate the heterodimerization between the purified bacterial expressed FXR and RXR $\alpha$

ligand binding domains (LBD). Detection of the associated LBD's are measured by time resolved fluorimetry (TRF). The purified LBD of FXR is labeled with biotin then mixed with stoichiometric amounts of europium labeled streptavidin (Wallac Inc). The purified LBD of RXR $\alpha$  is labeled with  
5 CY5<sup>TM</sup>. Equimolar amounts of each modified LBD are mixed together and allowed to equilibrate for at least 1 hour prior to the addition to either variable or constant concentrations of the sample for which the affinity is to be determined. After equilibration, the time-resolved fluorescent signal is quantitated using a fluorescent plate reader. The affinity of the test compound  
10 is estimated from a plot of fluorescence versus concentration of test compound added.

A basal level of FXR:RXR $\alpha$  heterodimer formation is observed in the absence of added ligand. Ligands that promote heterodimer formation induce a concentration-dependent increase in time-resolved fluorescent signal.  
15 Compounds which bind equally well to both monomeric FXR and to the FXR:RXR $\alpha$  heterodimer would be expected to give no change in signal whereas ligands which bind preferentially to the monomeric receptor would be expected to induce a concentration-dependent decrease in the observed signal.

## 20 METHODS & MATERIALS

### Advance Preparation:

#### Human Farnasoid X Receptor alpha Ligand Binding Domain

Human FXR $\alpha$  Ligand Binding Domain (FXR $\alpha$  LBD) was expressed in E.coli strain BL21 (DE3) as an amino-terminal polyhistidine tagged fusion  
25 protein. Expression was under the control of an IPTG inducible T7 promoter. DNA encoding this recombinant protein was subcloned into the pRSET-A expression vector (Invitrogen). The coding sequence of Human FXR $\alpha$  LBD was derived from Genbank accession number U 68233 (amino acids 222 to 472).

30 Ten-liter fermentation batches were grown in Rich P<sub>0</sub><sub>4</sub> media with 0.1 mg/mL Ampicillin at 25°C for 12 hours, cooled to 9°C and held at that

temperature for 36 hours to a density of  $OD_{600} = 14$ . At this cell density, 0.25 mM IPTG was added and induction proceeded for 24 hours at 9°C, to a final  $OD_{600} = 16$ . Cells were harvested by centrifugation (20 minutes, 3500g, 4°C), and concentrated cell slurries were stored in PBS at -8°C.

5        Purification of Receptor Ligand Binding Domain

Routinely, 30-40 g cell paste (equivalent to 2-3 liters of the fermentation batch) was resuspended in 200-250 mL TBS, pH 7.2 (25mM Tris, 150 mM NaCl). Cells were lysed by passing 3 times through a French Press and cell debris was removed by centrifugation (30 minutes, 20,000g, 4°C). The  
10        cleared supernatant was filtered through coarse pre-filters, and TBS, pH 7.2, containing 500 mM imidazole was added to obtain a final imidazole concentration of 50mM. This lysate was loaded onto a column (6 x 8 cm) packed with Sepharose [Ni<sup>++</sup>charged] Chelation resin (Pharmacia) and pre-equilibrated with TBS pH 7.2/ 50mM imidazole. After washing to baseline  
15        absorbance with equilibration buffer, the column was washed with one column volume of TBS pH 7.2 containing 90mM imidazole. FXR $\alpha$ LBD was eluted directly with 365 mM imidazole. Column fractions were pooled and dialyzed against TBS, pH 7.2, containing 0.5mM EDTA and 5mM DTT. The  
20        dialyzed protein sample was concentrated using Centri-prep 10 K (Amicon) and subjected to size exclusion, using a column (3 x 90 cm) packed with Sepharose S-75 resin (Pharmacia) pre-equilibrated with TBS, pH 7.2, containing 0.5mM EDTA and 5mM DTT.

Biotinylation of FXR

Purified FXR $\alpha$  LBD was desalted/buffer exchanged using PD-10 gel  
25        filtration columns into PBS [100mM NaPhosphate, pH 7.2, 150mM NaCl]. FXR $\alpha$  LBD was diluted to approximately 10  $\mu$ M in PBS and five-fold molar excess of NHS-LC-Biotin (Pierce) was added in a minimal volume of PBS. This solution was incubated with gentle mixing for 30 minutes at room temperature. The biotinylation modification reaction was stopped by the  
30        addition of 2000x molar excess of Tris-HCl, pH 8. The modified FXR $\alpha$  LBD

was dialyzed against 4 buffer changes, each of at least 50 volumes, PBS containing 5mM DTT, 2mM EDTA and 2% sucrose. The biotinylated FXR $\alpha$  LBD was subjected to mass spectrometric analysis to reveal the extent of modification by the biotinylation reagent. In general, approximately 95% of the protein had at least a single site of biotinylation; and the overall extent of biotinylation followed a normal distribution of multiple sites, ranging from one to nine.

#### RXR $\alpha$ LBD

RXR $\alpha$  LBD was prepared and labeled with CY5<sup>TM</sup> in accordance with the procedures set forth in example 1.

#### Preparation of CY5<sup>TM</sup> -RXR:Streptavidin-(Europium Chelate)-FXR Complex

Equimolar concentrations of biotinylated FXR and streptavidin-conjugated europium chelate were incubated in assay buffer containing 10 mM DTT for at least 10 minutes. To this solution an equimolar concentrations of Cy5<sup>TM</sup> labeled RXR $\alpha$  was added and allowed to equilibrate for at least 30 min. The premixed receptor was then added in a one-step addition to the compound plate, utilizing e.g., a Titertek Multidrop 384.

#### Materials:

Assay Buffer: 50 mM KCl, 0.1 mg/mL BSA, 10 mM DTT, and 50 mM Tris (pH 8) The stock buffer is made by dissolving 2.853g Tris base, 4.167 g Tris hydrochloride, 3.73 g KCl, and 0.1 g fatty acid free bovine serum albumin, in 1 L of deionized water. The pH is checked and adjusted to 8.0, if necessary, before adjusting to final volume. 0.154 g of solid DTT is added per 100 mL of buffer just before the start of an experiment.

BSA, fatty acid free

DTT

KCl

Europium labeled Streptavidin: (Wallac CR28-1 00)

Tris Hydrochloride

96 well plates: polypropylene for intermediate dilutions (Costar #3794)

and either a clear-bottomed white SPA plates (Costar #3632) or a black Polyfiltronics plate (UP350 PSB) for assays.

Methods: The methods, data reduction and interpretation of results are  
5 as described in example 1 and the results are shown in Figure 2.

### Example 3

A novel fluorescence resonance energy transfer (FRET) assay as described further infra, was used to test whether putative ligands bound to a nuclear receptor, using FXR as an example. The FRET assay is based upon  
10 the principle that ligands induce conformational changes in nuclear receptors that facilitate interactions with nuclear receptor coactivator proteins required for transcriptional activation. In an example, the ligand binding domain of FXR labeled with fluorophore allophycocyanin (APC) was incubated with a peptide containing the nuclear receptor interaction domain from the SRC-1  
15 coactivator labeled with europium cryptate.

Both the transactivation and ligand-binding assays typically used to determine activity of putative nuclear receptor activators assess the effect of test ligands on isolated receptor. However, a large proportion of the known orphan nuclear receptors interact with cofactor or coactivator proteins as a  
20 complex. Therefore, the present invention suggests the possibility that ligand binding to nuclear receptors may be modulated by the receptor's complexation with a cofactor peptide. The ability of ligand to induce changes in the degree of this complex was then used as a basis for an inventive assay for the discovery of nuclear receptor ligands. Certain sequences of the  
25 cofactor may only be required to interact with the nuclear receptor. Various sequences of the two cofactor proteins SRC-1 and CBP were synthesized and tested in HTRF and Biacore to determine the best sequences to use. The peptide, CPSSHSSLTERHKILHRLQLQEGSPS-CONH<sub>2</sub> (SEQ ID NO.:1), i.e., SRC-1(LCD2,676-700) was used in screening efforts with FXR and this  
30 forms a further aspect of this invention.

Coactivator proteins interact with nuclear receptors in a ligand-



dependent manner and augment transcription (9). A short amphipathic  $\alpha$ -helical domain that includes the amino acid motif LXXLL (L is Leu and X is any other amino acid) serves as the interaction interface between these coactivator molecules and the ligand-dependent activation function (AF-2) located in the COOH-terminus of the nuclear receptor LBD (10). To test whether ligands would induce a conformation of FXR that favors coactivator binding, a cell-free ligand-sensing assay utilizing fluorescence resonance energy transfer (FRET) to monitor allosteric interaction of a peptide based on the sequence of the steroid receptor coactivator 1 (SRC1) with the receptor was established. The use of FRET to monitor macromolecular complex formation is well established, particularly for immunoassays (11), and this detection methodology has recently been extended to characterize ligand binding to nuclear receptors (12).

Human FXR LBD was prepared and fluorescently labeled as described in Example 2. The LBD of human FXR was labeled with the fluorophore allophycocyanin and incubated with a peptide derived from the second LXXLL (SEQ ID NO.:1) motif of SRC1 (amino acids 676 to 700) that was labeled with europium chelate. The FRET ligand-sensing assay was performed by incubating 10 nM of the biotinylated FXR LBD that was labeled with streptavidin-conjugated allophycocyanin (Molecular Probes) and 10 nM of the SRC1 peptide [amino acids 676 to 700, 5'-biotin-CPSSHSSLTERHKILHRLQLQEGSPS-CONH<sub>2</sub>] (SynPEP) that was labeled with streptavidin-conjugated europium chelate (Wallac), in 50 mM Tris pH 8, 50 mM KCl, 0.1 mg/ml BSA, 1 mM EDTA, and 10 mM DTT, in the presence of test compound for 2 hours at 22°C. Data were collected using a Wallac Victor™ fluorescence reader in a time-resolved mode. The relative fluorescence was measured at 665nm and the data reduction was as described in Example 1.

Preparation of Streptavidin-(Europium Chelate)-SRC1:Streptavidin-(APC)-FXR Complex

Europium labeled Streptavidin: (Wallac CR28-100)

Tris Hydrochloride

96 well plates: polypropylene for intermediate dilutions (Costar #3794)  
and either a clear-bottomed white SPA plates (Costar #3632) or a black

5 Polyfiltronics plate (UP350 PSB) for assays.

## RESULTS

Ligands increased the interaction between FXR and the SRC1 peptide as determined with time-resolved FRET. Dose response analysis showed  
10 that the ligands increased the amount of SRC1 peptide bound to the FXR LBD. A typical saturable concentration response curve characteristic of specific interaction was observed.

As used in the claims for this assay, "nuclear receptor coactivator peptide" means a peptide whose affinity for the receptor is changed in the  
15 presence of ligand and which has a LXXLL motif. Examples of coactivator peptides useful for ligand identification by this method that have been demonstrated to interact with FXR include SRC-1 and those listed below:

1. B-QEQLSPKKKENNALLRYLLDRDDPS-CONH<sub>2</sub> (SEQ ID NO.: 2), ACTR (734-758), RAC3 (724-748), SRC-3 (724-748), AIB1 (724-748), pCIP (716-  
20 740)
2. B-QEPVSPKKKENALLRYLLDKDDTKD-CONH<sub>2</sub> (SEQ ID NO.:3), TIF2 (732-756)
3. B-GSTHGTSLKEKHILHRLQDSSSPVD-CONH<sub>2</sub> (SEQ ID NO.:4), TIF2 (676-702)
- 25 4. B-SNMHGSLQEKHRILHKLLQNGNSPAE-CONH<sub>2</sub> (SEQ ID NO.:5), pCIP (664-690), RAC3 (671-697), ACTR (681-707), AIB1 (671-697)

The sequences of peptides 1 and 4 appear in a number of coactivators, hence the multiple names. The "B" in the sequences stands for biotinylated, which is a modification that allows attachment of the peptide during the  
30 analysis.

The abbreviations used in the examples are included below.

	ACTR	Activator for Thyroid Hormone and Retinoid Receptors
	AIB1	Amplified in Breast Cancer
	APC	Allophycocyanin
5	APMSF	p-Amidinophenylmethanesulfonylfluoride, HCl
	Bestatin	[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl]-Leucine
	BSA	bovine serum albumin
	CHAPS	(3-[3-Cholamidopropyl]-dimethylammonio)-1-propanesulfonate
	CPM	counts per minute
10	DMSO	dimethylsulfoxide
	DTT	dithiothreitol
	EDTA	Ethylenediaminetetraacetic acid
	FXR	Farnesoid X Receptor
	IBTG	isopropyl- $\beta$ -D-thiogalactopyranoside
15	LBD	ligand binding domain
	LXR	Liver X Receptor
	OD <sub>600</sub>	optical density at 600 nm
	PBS	phosphate buffered saline [100mM NaPhosphate, pH 7.2, 50mM NaCl]
20	pCIP	Co-Integrator Protein
	RAC	Receptor Activated Cofactor
	RPM	revolutions per minute
	RXR	Retinoid X Receptor
	SA-APC	Streptavidin Crosslinked Allophycocyanin
25	SPA	Scintillation Proximity Assay
	SRC	Steroid Receptor Cofactor
	TIF	Transcriptional Intermediary Factor
	Tris	tris-(Hydroxymethyl)-aminomethane

The following references are noted and the entire disclosure of each is herein incorporated by reference

1. Apfel., R.H., Benbrook; D., Lemhardt, E., Ortiz, M.A., Salbert, G. And  
5 Pfahl, M. "A novel orphan receptor specific for a subset of TREs and its  
interaction with the retinoid/thyroid hormone receptor superfamily" Mol. Cell.  
Biol. 14, 7025-7035 (1994)
2. Willy PJ. Umesono K. Ong ES. Evans RM. Heyman RA. Mangelsdorf  
DJ. "LXR, a nuclear receptor that defines a distinct retinoid response  
10 pathway" Genes & Development. 9:1033-45 (1995)
3. Shinar, D.M., Endo, N., Rutledge, S.J., Vogel, R., Rodan, G.A. and  
Schmidt, A. "NER, a new member of the gene family encoding the human  
steroid hormone nuclear receptor" Gene 147, 273-276 (1994)
4. Janowski BA. Willy PJ. Devi TR. Falck JR. Mangelsdorf DJ. "An  
15 oxysterol signalling pathway mediated by the nuclear receptor LXR alpha"  
Nature.383: 728-31, (1996)
5. Lehmann JM. Kliewer SA. Moore LB. Smith-Oliver TA. Oliver BB. Su  
JL. Sundseth SS. Winegar DA. Blanchard DE. Spencer TA. Willson TM.  
"Activation of the nuclear receptor LXR by oxysterols defines a new hormone  
20 response pathway" Journal of Biological Chemistry.272: 3137-40 (1997)
6. Mangelsdorf, D.J. and Evans, R.M. "The RXR Heterodimers and  
Orphan Receptors" Cell 83: 841-850 (1995)
7. Mukherjee R, Davies, P.J., Crombie, D.L., Bischoff, E.D., Cesario, R.M.,  
Jow, L., Hamann, L.G., Boehm, M.F., Mondon, C.E., Nadzan, A.M., Paterniti  
25 Jr., J.R., and  
Heyman R.A. Sensitization of diabetic and obese mice to insulin by retinoid X  
receptor agonists. Nature 386: 407-410 (1997)
8. Forman BM. Goode E. Chen J. Oro AE. Bradley DJ. Perlmann T.  
Noonan DJ. Burka LT. McMorris T. Lamph WW. et al "Identification of a  
30 nuclear receptor that is activated by farnesol metabolites" Cell 81:687-693  
(1995)

9. C. K. Glass, D. W. Rose, M. G. Rosenfeld, *Curr. Opin. Cell Biol.* **9**, 222 (1997); D. Moras and H. Gronemeyer, *Curr. Opin. Cell Biol.* **10**, 384 (1998).
10. B. Le Douarin et al., *EMBO J.* **15**, 6701 (1996); D. M. Heery, E. Kalkhoven, S. Hoare, M. G. Parker, *Nature* **387**, 733 (1997); G. Krey et al., *Mol. Endocrinol.* **11**, 779 (1997).
11. E. Soini, I. Hemmila, P. Dahlen, *Ann. Biol. Clin.* **48**, 567 (1990); E. F. Gudgin Dickson, A. Pollak, E. P. Diamandis, *J. Photochem. Photobiol.* **27**, 3 (1995).
12. G. Zhou et al., *Mol. Endocrinol.* **12**, 1594 (1998); L. Paige et al., *Proc. Natl. Acad. Sci USA.* **96**, 3999 (1999).

We claim:

1. A method for the rapid determination of a ligand for a nuclear receptor which comprises contacting a component to be tested with an isolated nuclear receptor ligand binding domain which is associated with a first marking component, and a nuclear receptor coactivator peptide associated with a second marking component, and measuring the interaction between the marking components to determine whether the component to be tested modifies binding between the nuclear receptor ligand binding domain and the nuclear receptor coactivator peptide.
2. The method of claim 1, wherein the first marking component is a radioactive marker and the second marking component is a SPA bead.
3. The method of claim 1, wherein the first marking component is a first fluorescent dye emitting at an emitting wavelength which excites the second marking component which is a second fluorescent dye.
4. The method of claim 1, wherein the nuclear receptor is Farnesoid X Receptor ligand binding domain.
5. The method of claim 1 wherein the nuclear receptor coactivator peptide is SEQ ID NO.:1, SEQ ID NO.:2, SEQ ID NO.:3, SEQ ID NO.:4, SEQ ID NO.:5.
6. The method of claim 2, wherein the interaction of the markers is determined by scintillation proximity.
7. The method of claim 3, wherein the interaction of the markers is determined by homogenous time-resolved fluorimetry.
8. The method of claim 1, wherein the interaction of the marking

components is measured by comparing a signal produced by a combination of the nuclear receptor coactivator peptide, the isolated nuclear receptor binding domain and the component to be tested with a signal produced by a combination of the nuclear receptor coactivator peptide and the isolated  
5 nuclear receptor ligand binding domain in the absence of the component to be tested.

9. A method of identifying compounds for the treatment of diseases or disorders modulated by FXR, comprising the step of determining whether the  
10 compound interacts directly with FXR, wherein a compound that interacts directly with FXR is a compound for the treatment.

10. A method for the rapid determination of a ligand for a nuclear receptor which comprises contacting a component to be tested with an isolated  
15 nuclear receptor ligand binding domain which is associated with a first marking component, and a heterodimeric partner for the nuclear receptor ligand binding domain associated with a second marking component, and measuring the interaction between the marking components to determine whether the component to be tested modifies heterodimerization.

20

11. The method of claim 10, wherein the first marking component is a radioactive marker and the second marking component is a SPA bead.

12. The method of claim 10, wherein the first marking component is a first  
25 fluorescent dye emitting at an emitting wavelength which excites the second marking component which is a second fluorescent dye.

13. The method of claim 10 wherein the heterodimeric partner is an RXR, a PPAR, LXR $\alpha$ , LXR $\beta$ , ER  $\alpha$ , ER $\beta$ , CAR  $\alpha$ , an HNF4 , an NGFIB , PXR, PHR,  
30 EAR-1, EAR-2, TR, RAR, ERRs or RAR.

14. The method of claim 11, wherein the interaction of the markers is determined by scintillation proximity.

15. The method of claim 12, wherein the interaction of the markers is  
5 determined by homogenous time-resolved fluorimetry.

16. The method of claim 10, wherein the interaction of the marking  
components is measured by comparing a signal produced by a combination  
of the heterodimeric partner, the isolated nuclear receptor binding domain  
10 and the component to be tested with a signal produced by a combination of  
the heterodimeric partner and the isolated nuclear receptor ligand binding  
domain in the absence of the component to be tested.






Fig. 1




Fig. 2  
2/2

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/24956

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) :G01N 33/53; C12Q 1/70, 3/00

US CL :435/3, 5, 7.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/3, 5, 7.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US. 5,776,699 A (KLEIN et al) 07 July 1998, col. 6-col. 7.	1, 2, 4-6 and 8
A	MANGELSDORF. D.J. The RXR Heterodimers and Orphan Receptors. Cell. 15 December 1995, Vol. 83. pages 841-850, see entire document.	1, 2, 4-6 and 8
Y	MUKHERJEE. R. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 27 March 1997, Vol. 386. pages 407-410, especially page 410.	1, 2, 4-6 and 8
Y	US 4,568,649 A (BERTOGLIO-MATTE) 04 February 1986, col. 3-col. 4.	1, 2, 4-6 and 8
Y	US 5,670,360 A (THORENS) 23 September 1997, see col. 11, col. 12.	1, 2, 4-6 and 8



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 FEBRUARY 2000

Date of mailing of the international search report

29 FEB 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRETT L NELSON

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No. ....  
PCT/US99/24956

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1, 2, 4-6 and 8

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/24956

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST, DIALOG, EMBASE, SCISEARCH, MEDLINE, BIOSIS  
search terms: nuclear receptor, ligand binding domain, label, radioactive, coactivator protein, SPA bead, FXR, Farnesoid X Receptor, Scintillation

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-8, drawn to a method for the rapid determination of a ligand for a nuclear receptor employing an isolated receptor ligand binding domain and a nuclear receptor coactivator peptide.

Group II, claim 9, drawn to a method to identifying compounds for the treatment of diseases or disorders.

Group III, claims 10-16, drawn to a method for the rapid determination of a ligand for a nuclear receptor employing an isolated receptor ligand binding domain and a heterodimeric partner for the nuclear receptor ligand binding domain.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species correspond to Groups I and III and are as follows:

- a) radioactive markers (claims 2, 6, 11, and 14); and
- b) fluorescent markers (claims 3, 7, 12, and 15).

The following claims are generic: claims 1, 4, 5, and 8 are generic to Group I and claims 10, 13 and 16 are generic to Group III.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the groups recite different methods which employ different reagents, have different steps, and yield different results and PCT rules do not provide for multiple methods.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the species recite different products which have different structures and are detected differently.